Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary Russell RosenbergRogelio BracerasChad Ruoff COMMENTARY Open access 27 September 2023 Pages: 1805 - 1820
Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit Rita SattlerBryan J. TraynorAttendees of the inaugural C9ORF72 FTD/ALS Summit COMMENTARY Open access 17 October 2023 Pages: 1821 - 1843
Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE Taoufik AlsaadiDeeb M. KayedSuhail Al-Rukn GUIDELINES Open access 04 October 2023 Pages: 1845 - 1865
Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment Angelo GhezziR. F. Neuteboom REVIEW Open access 08 September 2023 Pages: 1867 - 1881
Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer’s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion Arthur EsquerFrédéric BlancNicolas Collongues REVIEW Open access 09 October 2023 Pages: 1883 - 1907
No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review] Scott D. NewsomeCherie BinnsJune Halper REVIEW Open access 11 October 2023 Pages: 1909 - 1935
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study Jason AldredEric Freire-AlvarezVictor S. C. Fung ORIGINAL RESEARCH Open access 26 August 2023 Pages: 1937 - 1958
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study Jason AldredEric Freire-AlvarezVictor S. C. Fung Correction Open access 10 October 2023 Pages: 1959 - 1960
Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021 Crystal WatsonDhanalakshmi ThirumalaiKiren Kresa-Reahl ORIGINAL RESEARCH Open access 08 September 2023 Pages: 1961 - 1979
Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Noboru ImaiYuki IsogaiNobuyuki Koga ORIGINAL RESEARCH Open access 11 September 2023 Pages: 1981 - 1991
Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis Shigekazu KitamuraTakao TakeshimaMiki Hasebe ORIGINAL RESEARCH Open access 12 September 2023 Pages: 1993 - 2006
Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial Mamoru ShibataAtsuko NihiraMika Komori ORIGINAL RESEARCH Open access 12 September 2023 Pages: 2007 - 2019
Effect of PLA2G6 and SMPD1 Variants on the Lipid Metabolism in the Cerebrospinal Fluid of Patients with Parkinson's Disease: A Non-targeted Lipidomics Study Yongang LiGuiKai JiYaxing Gui ORIGINAL RESEARCH Open access 14 September 2023 Pages: 2021 - 2040
Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells Radu TanasescuNanci FrakichCris S. Constantinescu ORIGINAL RESEARCH Open access 16 September 2023 Pages: 2041 - 2052
Burden of Medication Overuse in Migraine: A Cross-sectional, Population-Based Study in Five European Countries Using the 2020 National Health and Wellness Survey (NHWS) Agnete Skovlund DissingXin Ying LeeLene Hammer-Helmich ORIGINAL RESEARCH Open access 20 September 2023 Pages: 2053 - 2065
Rule-Based Identification of Individuals with Mild Cognitive Impairment or Alzheimer’s Disease Using Clinical Notes from the United States Veterans Affairs Healthcare System Byron J. AguilarDonald MillerWeiming Xia ORIGINAL RESEARCH Open access 25 September 2023 Pages: 2067 - 2078
Experience of Daily Life with Generalized Myasthenia Gravis: A Qualitative Investigation and Assessment of Instrument Content Validity Christopher A. HartfordSteven A. ShermanDiana Rofail ORIGINAL RESEARCH Open access 25 September 2023 Pages: 2079 - 2099
Identification of miRNAs Involved in Intracranial Aneurysm Rupture in Cigarette-Smoking Patients Hanbin WangLuxuan WangLijian Zhang ORIGINAL RESEARCH Open access 04 October 2023 Pages: 2101 - 2119
Predicting of Mechanical Ventilation and Outcomes by Using Models and Biomarker in Guillain-Barré Syndrome Jiajia YaoRumeng ZhouZuneng Lu ORIGINAL RESEARCH Open access 04 October 2023 Pages: 2121 - 2132
Cost-Effectiveness of Tonic Motor Activation (TOMAC) Therapy for Patients with Restless Legs Syndrome: An Exploratory Analysis Anne M. RyschonKhoa N. CaoJan B. Pietzsch ORIGINAL RESEARCH Open access 12 October 2023 Pages: 2133 - 2146
Association Between Serum Neurofilament Light Chain and Cognitive Performance Among Older Adults in the United States: A Cross-Sectional Study Yuanyuan GaoDan SuShu Wang ORIGINAL RESEARCH Open access 16 October 2023 Pages: 2147 - 2160
Evaluating Perceived Fatigue within an Adult Spinal Muscular Atrophy Population Lisa BelterIlse PetersonJill Jarecki ORIGINAL RESEARCH Open access 19 October 2023 Pages: 2161 - 2175
Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study José E. Meca-LallanaJosé M. Prieto GonzálezCristina Llarena ORIGINAL RESEARCH Open access 20 October 2023 Pages: 2177 - 2193
Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis” Pelayo Nieto-GómezCelia Castaño-Amores LETTER Open access 14 September 2023 Pages: 2195 - 2197
Response to Letter to the Editor Regarding “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis” Brittney LagerJacob LisenoJames B. Lewin LETTER Open access 14 September 2023 Pages: 2199 - 2203
